National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival 

Slides:



Advertisements
Similar presentations
The PSA Era is not Over for Prostate Cancer
Advertisements

Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: a Systematic Review and Meta-Analysis  Gang Liu, Yulei Ma, Shouhua Wang, Xiancheng.
Volume 58, Issue 4, Pages (October 2010)
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Volume 65, Issue 3, Pages (March 2014)
Volume 63, Issue 5, Pages (May 2013)
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients 
Prostate Cancer: Highlights from 2006
European Urology Oncology
Volume 59, Issue 5, Pages (May 2011)
Volume 68, Issue 3, Pages (September 2015)
European Urology Oncology
Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis  Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni,
New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 71, Issue 4, Pages (April 2017)
European Urology Oncology
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
European Urology Oncology
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 73, Issue 2, Pages (February 2018)
Volume 61, Issue 5, Pages (May 2012)
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis  Mohamad B. Sonbol, Belal Firwana, Talal.
Volume 65, Issue 3, Pages (March 2014)
Volume 67, Issue 3, Pages (March 2015)
Volume 64, Issue 5, Pages (November 2013)
European Urology Oncology
European Urology Oncology
Counselling the Prostate Cancer Patient
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
Volume 64, Issue 4, Pages (October 2013)
Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery
Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL,
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 72, Issue 2, Pages (August 2017)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study  Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,
European Urology Oncology
European Urology Oncology
Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA  Nawar Hanna, Quoc-Dien Trinh,
Testicular Cancer Variations in Time and Space in Europe
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Volume 74, Issue 4, Pages (October 2018)
Kidney Cancer: Highlights from 2006
Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
Bladder Cancer: Highlights from 2006
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?  Jean-Jacques Patard 
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Neal S Goldstein, MD  The Annals of Thoracic Surgery 
Axel Heidenreich  European Urology Supplements 
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Maximilian Burger, Ashish M. Kamat, David McConkey 
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.
European Urology Oncology
Presentation transcript:

National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival  Karin M. Hjelle, Tom B. Johannesen, Leif Bostad, Lars A.R. Reisæter, Christian Beisland  European Urology Oncology  Volume 1, Issue 3, Pages 252-261 (August 2018) DOI: 10.1016/j.euo.2018.04.001 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Flowchart for data extraction from the main database of the Cancer Registry of Norway according to the inclusion and exclusion criteria. MIM=minimally invasive method. European Urology Oncology 2018 1, 252-261DOI: (10.1016/j.euo.2018.04.001) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Temporal trends in the use of (A) partial nephrectomy and (B) radical nephrectomy for 2420 patients. Data points show the annual frequencies and the trend line demonstrates the joinpoint regression results. The annual percentage change (APC) was significantly different from zero at α=0.05 for partial nephrectomy, indicating a significant increase in this procedure. The small decrease in radical nephrectomy was not statistically significant. European Urology Oncology 2018 1, 252-261DOI: (10.1016/j.euo.2018.04.001) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Comparison of treatments in terms of percentage of procedures per year. (A) All approaches investigated. (B) Open radical nephrectomy (ORN) versus minimally invasive radical nephrectomy (MIM-RN). (C) Open partial nephrectomy (OPN) versus minimally invasive partial nephrectomy (MIM-PN). European Urology Oncology 2018 1, 252-261DOI: (10.1016/j.euo.2018.04.001) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 4 Distribution and changes in treatment in the 19 counties in Norway in the first half (2008–2010) and second half (2011–2013) of the study period. PN during (A) 2008–2010 and (B) 2011–2013. (C) PN for tumors ≤4cm during (C) 2008–2010 and (D) 2011–2013. MIM-RN for tumors of 4.1–7cm during (E) 2008–2010 and (F) 2011–2013. MIM includes pure laparoscopic, hand-assisted, and robot-assisted laparascopic methods. Overall, the variation in PN among counties ranged from 26% to 59%. The variation in PN rate ranged from 36% to 77% for tumors ≤4cm and from 2% to 28% for tumors of 4.1–7cm (data not shown). Counties with a PN rate of <25% PN in 2008 doubled the PN rate in 2013, whereas counties with a PN rate of 25–40% in 2008 increased this to approximately 60% in 2013. Four of the 19 counties generally used PN more often than RN during the study period. From the first to the second half of the study, the use of MIM-RN for tumors of 4.1–7cm became more widespread. PN=partial nephrectomy; MIM-RN=minimally invasive radical nephrectomy. European Urology Oncology 2018 1, 252-261DOI: (10.1016/j.euo.2018.04.001) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 5 Competing-risks analysis for partial nephrectomy (PN) and radical nephrectomy (RN). Probability of death (A) from kidney cancer versus death from all other causes; (B) from kidney cancer versus other cancers and noncancerous conditions; and (C) from all cancers (including kidney cancers) versus noncancerous conditions. European Urology Oncology 2018 1, 252-261DOI: (10.1016/j.euo.2018.04.001) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 252-261DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 252-261DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 252-261DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 252-261DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions